Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Timing for Bone Marrow Mononuclear Cells After Acute Myocardial Infarction

Condition:   Myocardial Infarction
Interventions:   Other: BMC therapy within 24 hours;   Other: BMC therapy within 3-7 days;   Other: BMC therapy within 7-30 days;   Other: PCI only
Sponsors:   The First Affiliated Hospital of Dalian Medical University;   Fudan University
Completed - verified April 2015

Women's Health Initiative Strong and Healthy Study

Conditions:   Myocardial Infarction;   Stroke;   Cardiovascular Mortality;   Hip Fractures;   Falls;   Mortality;   Venous Thromboembolic Event;   Peripheral Artery Disease
Intervention:   Behavioral: Physical Activity
Sponsors:   Fred Hutchinson Cancer Research Center;   University of California, San Diego;   Stanford University;   National Heart, Lung, and Blood Institute (NHLBI)
Enrolling by invitation - verified April 2015

Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by Ticagrelor

Condition:   Myocardial Infarction
Interventions:   Drug: Ticagrelor;   Drug: Prasugrel
Sponsors:   VU University Medical Center;   Erasmus Medical Center
Not yet recruiting - verified April 2015

Short-Term Application of Tocilizumab Following Myocardial Infarction

Condition:   Myocardial Infarction
Interventions:   Drug: Tocilizumab;   Drug: Placebo
Sponsor:   Keesler Air Force Base Medical Center
Recruiting - verified April 2015

Morbidity and Mortality in Patients With Hypertrophic Cardiomyopathy: a CALIBER Study

Condition:   Hypertrophic Cardiomyopathy
Intervention:   Other: No intervention
Sponsors:   University College, London;   Inherited Cardiac Diseases Unit, The Heart Hospital, London
Active, not recruiting - verified April 2015

COcoa Supplement and Multivitamin Outcomes Study

Conditions:   Cardiovascular Disease;   Cancer
Interventions:   Dietary Supplement: Cocoa extract;   Dietary Supplement: Multivitamin;   Dietary Supplement: Cocoa extract placebo;   Dietary Supplement: Multivitamin placebo
Sponsors:   Brigham and Women's Hospital;   Fred Hutchinson Cancer Research Center;   Mars, Inc.;   Pfizer
Not yet recruiting - verified April 2015

Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke Clinical Research Institute
Not yet recruiting - verified April 2015

Non-contrast Cardiac CT as a Risk Stratification Tool in Patients With Non-cardiac Chest Pain

Condition:   Coronary Artery Disease
Intervention:   Other: Non-contrast Cardiac CT scan
Sponsor:   University of Southern Denmark
Recruiting - verified April 2015

Medtronic Resolute Onyx Core (2.25 mm - 4.0 mm) Clinical Study

Condition:   Coronary Artery Disease
Intervention:   Device: Resolute Onyx Stent - 2.25 mm - 4.0 mm
Sponsor:   Medtronic Vascular
Not yet recruiting - verified April 2015

Epidural Anesthesia Within an Enhanced Recovery Pathway in Reducing Pain in Patients Undergoing Gynecologic Surgery

Conditions:   Intraoperative Complication;   Malignant Female Reproductive System Neoplasm;   Pain
Interventions:   Drug: Epidural analgesia;   Other: Intraoperative Complication Management and Prevention;   Procedure: Pain Therapy
Sponsors:   University of Wisconsin, Madison;   National Cancer Institute (NCI)
Recruiting - verified April 2015

Prospective, Interventional Study Evaluating the Feasibility and Safety of the Esophageal Cooling Device

Condition:   Traumatic Brain Injury
Intervention:   Device: Esophageal Cooling Device (ECD), manufactured by Advanced Cooling Therapy, Inc.
Sponsors:   Advanced Cooling Therapy, LLC;   Dnipropetrovsk State Medical Academy
Not yet recruiting - verified April 2015

A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: erlotinib;   Drug: BGB324
Sponsor:   BerGenBio AS
Recruiting - verified April 2015

Researches of Retinal Artery Lesions and Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   Capital Medical University
Active, not recruiting - verified April 2015

Test Efficacy With Bioresorbable Polymer Coating Versus Bioresorbable Polymer Backbone (ISAR-RESORB)

Condition:   Coronary Stenosis
Interventions:   Device: SYNERGY EES;   Device: ABSORB [BVS]
Sponsor:   Deutsches Herzzentrum Muenchen
Not yet recruiting - verified April 2015

Medtronic Resolute Onyx 2.0 mm Clinical Study

Condition:   Coronary Artery Disease
Intervention:   Device: Resolute Onyx Stent - 2.0 mm
Sponsor:   Medtronic Vascular
Not yet recruiting - verified April 2015

CRIC-Visceral Adiposity and Physical Fitness in Chronic Kidney Disease

Conditions:   Renal Insufficiency, Chronic;   Obesity
Intervention:  
Sponsors:   The Cleveland Clinic;   University of Pennsylvania;   Case Western Reserve University;   University of Michigan;   University of Illinois at Chicago;   University of Maryland;   MetroHealth Medical Center
Recruiting - verified April 2015

Brilinta Taiwan Post Approval Safety Study

Condition:   Non ST-elevation Myocardial Infarction
Intervention:   Drug: Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
Sponsor:   AstraZeneca
Not yet recruiting - verified April 2015

A Trial in Stable Intermediate Coronary Lesions and Grey-zone FFR Values

Conditions:   Grey-zone Fractional Flow Reserve;   Intermediate Coronary Lesions;   Stable Angina;   Coronary Physiology
Interventions:   Procedure: PCI;   Drug: Optimal Medical Therapy
Sponsors:   Golden Jubilee National Hospital;   British Heart Foundation;   University of Glasgow
Not yet recruiting - verified March 2015

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Conditions:   Polycythemia Vera;   Essential Thrombocythemia
Interventions:   Drug: RG7388;   Drug: Pegasys
Sponsors:   John Mascarenhas;   Genentech, Inc.;   Roche Pharma AG
Recruiting - verified April 2015

Immediate Versus Delayed Invasive Intervention for Non-STEMI Patients

Condition:   Myocardial Infarction
Interventions:   Procedure: Immediate invasive intervention;   Procedure: Delayed invasive intervention;   Device: Coronary artery stenting
Sponsor:   Clinical Centre of Serbia
Active, not recruiting - verified April 2015

CardiOvascular Risk and idEntificAtion of Potential High-risk Population in Acute Myocardial Infarction

Conditions:   Long-term Major Cardiovascular Events;   Myocardial Infarction;   Percutaneous Coronary Intervention
Interventions:   Device: Percutaneous coronary intervention;   Device: Percutaneous coronary intervention
Sponsors:   Kiyuk Chang;   The Catholic University of Korea;   Chonnam National University
Completed - verified April 2015

SONOlysis in Prevention of Brain InfaRctions During Internal Carotid Endarterectomy

Condition:   Internal Carotid Artery Stenosis
Intervention:   Device: sonolysis
Sponsors:   University Hospital Ostrava;   Military University Hospital, Prague;   Vitkovice Hospital, Ostrava;   Masaryk Hospital, Usti nad Labem;   České Budějovice Hospital;   University Hospital Hradec Kralove;   University Hospital Plzen, Plzen;   County Hospital Liberec, Liberec
Not yet recruiting - verified April 2015

Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)

Condition:   Hypertension
Interventions:   Device: Renal Denervation (Vessix);   Device: Renal Angiography
Sponsor:   Boston Scientific Corporation
Enrolling by invitation - verified April 2015

Weight Loss Referral for Healthier Survivorship in Obese Stage I-II Endometrial Cancer Survivors or Atypical Hyperplasia

Conditions:   Complex Endometrial Hyperplasia With Atypia;   Stage IA Uterine Corpus Cancer;   Stage IB Uterine Corpus Cancer;   Stage II Uterine Corpus Cancer
Interventions:   Behavioral: Weight Loss Specialist;   Other: Quality-of-Life Assessment;   Other: Medical Chart Review
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified April 2015

Jakarta Acute Coronary Syndrome Registry

Condition:   Acute Coronary Syndrome
Intervention:   Other: JAC Registry
Sponsor:   National Cardiovascular Center Harapan Kita Hospital Indonesia
Recruiting - verified April 2015

Outcome After Coronary Artery Bypass Grafting

Conditions:   Coronary Artery Disease;   Myocardial Infarction;   Angina Pectoris
Intervention:   Procedure: Coronary artery bypass surgery
Sponsors:   University of Oulu;   Universita di Verona;   Ospedali Riuniti Trieste;   University of Catania;   University of Leicester;   Centre Hospitalier Universitaire de Besancon;   Karolinska Institutet;   San Camillo Hospital, Rome;   Rennes University Hospital;   S. Anna Hospital;   Paracelsus Medical University;   Second University of Naples;   University of Parma
Recruiting - verified April 2015

"In Vivo" Comparison in Human Carotid Atherosclerosis: Plaque Neovascularization

Conditions:   Carotid Artery Disease;   Plaque Neovascularization
Interventions:   Other: Contrast enhanced ultrasound of the carotid plaque;   Other: Dynamic contrast-enhanced carotid plaque MRI
Sponsor:   Ospedale San Giovanni Bellinzona
Recruiting - verified April 2015

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Acetylsalicylic acid;   Drug: Rivaroxaban;   Drug: Clopidogrel;   Drug: Ticagrelor
Sponsors:   Janssen Research & Development, LLC;   Bayer;   Duke Clinical Research Institute;   Harvard Medical School
Not yet recruiting - verified April 2015

RuSsian RegisTry of Acute CoronaRy SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified April 2015

Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia

Condition:   Critical Limb Ischemia
Interventions:   Drug: rivaroxaban plus aspirin;   Drug: clopidogrel plus aspirin
Sponsors:   Ottawa Hospital Research Institute;   The Ottawa Hospital
Recruiting - verified April 2015

Left vs Right Radial Approach in the Setting of Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction

Condition:   Transradial Approach, Primary PCI, ST-segment Elevation Myocardial Infarction
Interventions:   Procedure: Left radial approach;   Procedure: Right radial approach
Sponsor:   Capital Medical University
Recruiting - verified September 2014

Canadian Alliance for Healthy Hearts and Minds

Condition:   Cardiovascular Diseases
Intervention:   Other: MRI
Sponsor:   Montreal Heart Institute
Recruiting - verified April 2015

Using Ripple Mapping to Guide Substrate Ablation of Scar Related Ventricular Tachycardia.

Conditions:   Monomorphic Ventricular Tachycardia;   Myocardial Infarction;   Dilated Cardiomyopathy
Interventions:   Device: Ripple Mapping guided VT ablation;   Device: Conventional VT ablation
Sponsor:   Imperial College London
Recruiting - verified July 2014

AOP2014 in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.

Condition:   Polycythemia Vera
Intervention:   Drug: Pegylated-Proline-interferon alpha-2b
Sponsors:   AOP Orphan Pharmaceuticals AG;   PharmaEssentia (Co-Sponsor for USA)
Recruiting - verified April 2015

Intravascular Ultrasound Guided Drug Eluting Stent Implantation in "All-comers" Coronary Lesions

Condition:   Coronary Artery Disease
Interventions:   Procedure: Angiography;   Procedure: IVUS;   Procedure: DES implantation
Sponsor:   The First Hospital of Nanjing Medical University
Recruiting - verified April 2015

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2015

Circadian Rhythms and Cardiovascular Risk

Condition:   Obstructive Sleep Apnea
Intervention:   Behavioral: Forced Desynchrony
Sponsor:   Oregon Health and Science University
Recruiting - verified April 2015

Pre-hospital Anti-fibrinolytics for Traumatic Coagulopathy and Haemorrhage (The PATCH Study)

Conditions:   Wounds and Injuries;   Acute Coagulopathy
Interventions:   Drug: Tranexamic Acid;   Drug: Placebo
Sponsors:   National Trauma Research Institute;   National Health and Medical Research Council, Australia
Recruiting - verified April 2015

HealthMap: an Interactive Health Plan Randomised Trial to Prevent Cardiovascular Disease in People With HIV

Conditions:   HIV;   Cardiovascular Disease
Intervention:   Other: Integrated self management support
Sponsors:   Karen Klassen;   Alfred Health;   Monash University;   Australasian Society for HIV Medicine;   National Association for People with HIV Australia;   National Health and Medical Research Council, Australia;   Victorian AIDS Council;   Department of Health, Victoria;   Flinders University;   Living Positive Victoria;   New South Wales Ministry of Health;   University of Melbourne;   Deakin University
Recruiting - verified April 2015

Immunological Profile in Relation to Cardiac Geometry in Hypertension

Condition:   Immune System Profile During Hypertensive Cardiac Remodeling
Intervention:  
Sponsor:   Neuromed IRCCS
Recruiting - verified April 2015

Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   Boehringer Ingelheim
Completed - verified April 2015

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

Condition:   Acute Myocardial Infarction
Interventions:   Biological: CSL112;   Biological: Placebo
Sponsor:   CSL Behring
Recruiting - verified April 2015

Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary Events

Condition:   Pulmonary Disease, Chronic Obstructive
Intervention:  
Sponsor:   Boehringer Ingelheim
Active, not recruiting - verified April 2015

Sequential Expansion of Comparative Effectiveness of Anticoagulants

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2015

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

Conditions:   Pulmonary Embolism;   Thromboembolism;   Thrombosis;   Venous Thrombosis;   Venous Thromboembolism
Interventions:   Drug: BAY 59-7939;   Drug: BAY 59-7939;   Drug: ASA
Sponsor:   Bayer
Recruiting - verified April 2015

Angioshield First-In-Human Study to Demonstrate the Preliminary Safety and Efficacy

Condition:   Coronary Artery Disease
Intervention:   Device: Angioshield
Sponsor:   Neograft Technologies, Incorporated
Active, not recruiting - verified April 2015

Understanding the Role of Autoimmune Disorders on the Initial Presentation of Cardiovascular Disease

Conditions:   Myocardial Infarction;   Ischemic Stroke;   Stroke;   Subarachnoid Haemorrhage;   Venous Thrombosis;   Transient Ischemic Attack;   Stable Angina Pectoris;   Unstable Angina;   Heart Failure;   Peripheral Arterial Disease;   Abdominal Aortic Aneurysm
Intervention:   Other: No intervention
Sponsors:   University College, London;   Wellcome Trust;   National Institute for Health Research, United Kingdom
Active, not recruiting - verified April 2015

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

Condition:   Atrial Fibrillation
Interventions:   Drug: Apixaban;   Drug: Parenteral heparin and/or oral Vitamin K antagonist
Sponsors:   Pfizer;   Bristol-Myers Squibb
Recruiting - verified April 2015

The Efficacy of Bariatric Surgery Compared to Medical Therapy in Controlling Type2 Diabetes Mellitus in Patients With Non Morbid Obesity.

Conditions:   Overweight;   Diabetes Type 2
Interventions:   Procedure: Laparoscopic Sleeve Gastrectomy;   Procedure: Laparoscopic Roux-en-Y Gastric Bypass;   Drug: Advanced Medical Therapy
Sponsor:   Hadassah Medical Organization
Recruiting - verified February 2015

Reduction in Infarct Size by Remote Per-postconditioning in Patients With ST-elevation Myocardial Infarction

Conditions:   Coronary Artery Disease;   Myocardial Infarction
Intervention:   Procedure: Primary Percutaneous Coronary Intervention
Sponsor:   John Pernow
Recruiting - verified April 2015

Nelfinavir in Systemic Lupus Erythematosus

Condition:   Systemic Lupus Erythematosus
Intervention:   Drug: Nelfinavir
Sponsors:   North Shore Long Island Jewish Health System;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified April 2015

Danhong Injection in the Treatment of Unstable Angina Pectoris

Condition:   Unstable Angina Pectoris
Interventions:   Drug: Danhong injection;   Other: Standard medical care;   Drug: Placebo
Sponsors:   China  Academy of Chinese Medical Sciences;   China Food and Drug Administration  
Recruiting - verified April 2015

A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Ticagrelor 90 mg;   Drug: Ticagrelor placebo
Sponsor:   AstraZeneca
Recruiting - verified April 2015

Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified April 2015

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

Conditions:   Acute Ischaemic Stroke;   Transient Ischaemic Attack.
Interventions:   Drug: ticagrelor;   Drug: Acetylsalicylic acid (ASA)
Sponsor:   AstraZeneca
Recruiting - verified April 2015

ISCHEMIA-Chronic Kidney Disease Trial

Conditions:   Cardiovascular Diseases;   Coronary Artery Disease;   Heart Diseases;   Myocardial Ischemia;   Kidney Disease;   End Stage Renal Failure on Dialysis
Interventions:   Procedure: Cardiac Catheterization;   Procedure: Coronary Artery Bypass Graft Surgery;   Procedure: Percutaneous Coronary Intervention;   Behavioral: Lifestyle;   Drug: Medication
Sponsors:   New York University School of Medicine;   New York University;   National Heart, Lung, and Blood Institute (NHLBI);   Vanderbilt University;   Albany Stratton VA Medical Center;   East Carolina University;   Duke University;   Stanford University;   Harvard University;   Columbia University
Recruiting - verified April 2015

Single Session Percutaneous Mechanical Thrombectomy for the Treatment of Ilio-femoral Deep Vein Thrombosis: A Preliminary Evaluation

Conditions:   Deep Vein Thrombosis;   Venous Thromboembolism
Intervention:   Device: Thrombectomy
Sponsor:   Ottawa Hospital Research Institute
Terminated - verified April 2015

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2015

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified April 2015

Colchicine in ST-elevation Myocardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Drug: Colchicine 2 mg loading dose; 0.5 mg bid for 5 days;   Drug: Placebo
Sponsor:   G.Gennimatas General Hospital
Recruiting - verified April 2015

GLORIA-AF Registry Program (Phase II/III)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2015

Resolute Integrity US Extended Length Sub-Study(RI-US XL)

Condition:   Coronary Artery Disease
Intervention:   Device: Resolute Integrity Stent
Sponsor:   Medtronic Vascular
Recruiting - verified April 2015

Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair

Condition:   Surgical Procedures
Interventions:   Drug: GSK1278863;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified April 2015

ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial

Condition:   Peripheral Endovascular Interventions
Intervention:   Drug: Bivalirudin
Sponsor:   The Medicines Company
Recruiting - verified July 2014

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure

Conditions:   Heart Failure;   Coronary Artery Disease
Interventions:   Drug: Rivaroxaban;   Drug: Placebo;   Other: Standard of care for heart failure and coronary artery disease
Sponsors:   Janssen Research & Development, LLC;   Bayer
Recruiting - verified April 2015

Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients

Conditions:   Stroke,;   Embolism
Intervention:   Other: Rivaroxaban ( Xarelto, BAY59-7939)
Sponsor:   Bayer
Recruiting - verified April 2015

ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial

Condition:   End Stage Renal Failure on Dialysis
Interventions:   Drug: Spironolactone;   Drug: Placebo
Sponsors:   University Hospital, Brest;   Central Hospital, Nancy, France;   Institut National de la Santé Et de la Recherche Médicale, France
Recruiting - verified April 2015

Preventing Stem Cell Transplant Complications With a Blood Separator Machine

Conditions:   MDS (Myelodysplastic Syndrome);   Myeloproliferative Disorder;   Lymphoma, Non-Hodgkin;   ALL (Acute B-Lymphoblastic Leukemia);   AML (Acute Meylogenous Leukemia
Intervention:   Device: Graft Manipulation (CD34+ Selection)
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2015

Antibody Treatment for Advanced Celiac Disease

Conditions:   Celiac Disease;   Celiac Sprue;   Gluten Enteropathy;   Gluten-Sensitive Enteropathy
Intervention:   Biological: Hu-Mik- Beta-1
Sponsors:   National Cancer Institute (NCI);   Mayo Clinic
Recruiting - verified March 2015

Sirolimus Eluting ORSIRO Stent Versus Biolimus-eluting NOBORI Stent

Conditions:   Coronary Artery Disease;   Ischemic Heart Disease
Intervention:   Device: Drug-eluting stent
Sponsor:   Odense University Hospital
Active, not recruiting - verified April 2015

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: rivaroxaban 2.5 mg;   Drug: rivaroxaban 15 mg;   Drug: rivaroxaban 10 mg;   Drug: aspirin (ASA);   Drug: vitamin K antagonist (VKA);   Drug: clopidogrel;   Drug: prasugrel;   Drug: ticagrelor
Sponsors:   Janssen Scientific Affairs, LLC;   Bayer
Recruiting - verified April 2015

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Condition:   Dyslipidemia
Interventions:   Biological: Evolocumab (AMG 145);   Other: Placebo;   Drug: Effective statin therapy
Sponsor:   Amgen
Recruiting - verified April 2015

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

Condition:   Peripheral Artery Disease
Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel
Sponsor:   AstraZeneca
Active, not recruiting - verified April 2015

Intracoronary Autologous Mesenchymal Stem Cells Implantation in Patients With Ischemic Dilated Cardiomyopathy

Condition:   Ischemic Dilated Cardiomyopathy
Intervention:   Other: BM-MSCs
Sponsors:   National University of Malaysia;   Cytopeutics Sdn Bhd
Active, not recruiting - verified April 2015

STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial

Conditions:   Intracerebral Haemorrhage;   Stroke
Interventions:   Drug: Tranexamic Acid;   Drug: Placebo
Sponsor:   Neuroscience Trials Australia
Recruiting - verified September 2014

Long-term Clinical Outcome in Patients Undergoing Remote Ischemic Conditioning Before Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction: a Follow-up Study

Condition:   ST-elevation Myocardial Infarction (STEMI)
Intervention:   Procedure: Remote ischemic perconditioning
Sponsors:   University of Aarhus;   Aarhus University Hospital;   Oxford University Hospitals NHS Trust;   The Hospital for Sick Children
Active, not recruiting - verified August 2013

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2015

CYCLosporinE A in Reperfused Acute Myocardial Infarction

Condition:   Acute Myocardial Infarction
Intervention:   Drug: Cyclosporine A
Sponsors:   Mario Negri Institute for Pharmacological Research;   Heart Care Foundation
Completed - verified October 2013

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Other: placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified April 2015

Danhong Injection in the Treatment of Chronic Stable Angina

Condition:   Chronic Stable Angina
Interventions:   Drug: Danhong injection;   Other: Standard medical care;   Drug: Placebo
Sponsors:   China  Academy of Chinese Medical Sciences;   China: State Food and Drug Administration
Recruiting - verified April 2015

An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System

Condition:   Coronary Artery Disease
Intervention:   Procedure: Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System (Resolute Integrity Stent)
Sponsor:   Medtronic Vascular
Active, not recruiting - verified April 2015

Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

Condition:   Smoking Cessation
Interventions:   Drug: placebo;   Drug: varenicline tartrate;   Drug: bupropion hydrochloride;   Drug: Nicotine Replacement Therapy Patch
Sponsor:   Pfizer
Recruiting - verified April 2015

Cyclosporine and Prognosis in Acute Myocardial Infarction (MI) Patients

Condition:   ST Elevation Acute Myocardial Infarction
Interventions:   Drug: Injection of Cyclosporin;   Drug: Placebo;   Procedure: Echocardiography
Sponsor:   Hospices Civils de Lyon
Active, not recruiting - verified April 2015

Role of Cerebral Oximetry In Reducing Delirium After Complex Cardiac Surgery

Condition:   Cardiac Disease
Interventions:   Device: Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter);   Other: An alarm threshold at 75% of the baseline rSO2 value
Sponsor:   University Health Network, Toronto
Active, not recruiting - verified April 2015

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2015

ABSORB II Randomized Controlled Trial

Condition:   Coronary Artery Disease
Interventions:   Device: Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System;   Device: Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
Sponsor:   Abbott Vascular
Active, not recruiting - verified April 2015

Patient-centered Outcomes Related to TReatment Practices in Peripheral Arterial Disease: Investigating Trajectories (PORTRAIT)

Conditions:   Peripheral Arterial Disease;   Quality of Life;   Quality of Care
Intervention:  
Sponsors:   Saint Luke's Health System;   Patient Centered Outcome Research Institute
Recruiting - verified April 2015

Fondaparinux EU-RMP (Adherence)

Conditions:   ST-elevation Myocardial Infarction;   Unstable Angina;   Non ST Segment Elevation Myocardial Infarction;   Acute Coronary Syndrome
Intervention:   Drug: fondaparinux
Sponsor:   GlaxoSmithKline
Completed - verified April 2015

Comparison Between FFR Guided Revascularization Versus Conventional Strategy in Acute STEMI Patients With MVD.

Conditions:   Myocardial Infarction;   Multivessel Coronary Artery Disease
Interventions:   Procedure: FFR-guided revascularisation strategy;   Procedure: randomised to guidelines group
Sponsors:   Maasstad Hospital;   Abbott Vascular;   St. Jude Medical
Recruiting - verified April 2015

Resolute Zotarolimus-Eluting Stent Versus the Taxus Liberte Paclitaxel-Eluting Stent for Percutaneous Coronary Intervention in China

Conditions:   Ischemic Heart Disease;   Stenotic Coronary Lesion;   Cardiovascular Diseases;   Arteriosclerosis;   Coronary Artery Disease
Interventions:   Device: Taxus Liberte Paclitaxel-Eluting Coronary Stent System;   Device: Resolute Zotarolimus-Eluting Coronary Stent System
Sponsor:   Medtronic Vascular
Active, not recruiting - verified April 2015

Remote Ischemic Preconditioning in High Risk Cardiovascular Surgery Patients

Conditions:   Death;   Stroke;   Low Cardiac Output Syndrome;   Myocardial Infarction;   Renal Failure;   Pulmonary Failure
Interventions:   Other: Remote ischemic preconditioning stimulus;   Other: control
Sponsor:   Queen's University
Recruiting - verified April 2015

Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients

Conditions:   Invasive Epithelial Ovarian Cancer;   Primary Peritoneal Carcinoma;   Fallopian Tube Cancer
Intervention:   Drug: Propranolol
Sponsor:   Washington University School of Medicine
Completed - verified April 2015

Evaluation of the Endeavor Resolute Zotarolimus-Eluting Coronary Stent System in a Real-World Patient Population in China

Conditions:   Ischemic Heart Disease;   Stenotic Coronary Lesion;   Cardiovascular Diseases;   Arteriosclerosis;   Coronary Artery Disease
Intervention:  
Sponsor:   Medtronic Vascular
Active, not recruiting - verified April 2015

EXCEL Clinical Trial

Conditions:   Chronic Coronary Occlusion;   Unprotected Left Main Coronary Artery Disease;   Stent Thrombosis;   Vascular Disease;   Myocardial Ischemia;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Artery Disease;   Coronary Restenosis
Interventions:   Device: Percutaneous Coronary Intervention;   Procedure: CABG
Sponsor:   Abbott Vascular
Active, not recruiting - verified April 2015

RESOLUTE Asia: Evaluation of the Endeavor Resolute Zotarolimus-Eluting Stent System in a Patient Population With Long Lesion(s) and/or Dual Vessels in Asia

Conditions:   Ischemic Heart Disease;   Stenotic Coronary Lesion;   Cardiovascular Diseases;   Arteriosclerosis;   Coronary Artery Disease
Intervention:   Device: Drug eluting stent treatment
Sponsor:   Medtronic Vascular
Active, not recruiting - verified April 2015

Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty

Condition:   Saphenous Vein Graft Atherosclerosis
Interventions:   Device: Bare Metal Stent;   Device: Drug-Eluting Stent;   Drug: Blinded clopidogrel;   Drug: Placebo;   Drug: Thienopyridine (open-label)
Sponsor:   Department of Veterans Affairs
Recruiting - verified April 2015

Troponin T as Risk Stratification Tool in Peripheral Arterial Occlusive Disease

Condition:   Peripheral Arterial Occlusive Disease
Intervention:  
Sponsors:   Heart Center Bad Krozingen;   Johann Wolfgang Goethe University Hospitals
Completed - verified April 2015

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Condition:   Ischemic Attack, Transient
Interventions:   Drug: Clopidogrel;   Drug: placebo
Sponsors:   University of California, San Francisco;   Neurological Emergencies Treatment Trials Network (NETT);   Medical University of South Carolina;   The EMMES Corporation
Recruiting - verified April 2015

A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma

Conditions:   Severe, Refractory Asthma;   Airway Inflammation;   Airflow Obstruction
Intervention:   Drug: Pioglitazone
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2015

Efficacy and Cost-Effectiveness of Cost-free Pharmacotherapy for Smoking Cessation for High-risk Smokers With Cerebrovascular Disease

Conditions:   Cerebrovascular Disorders;   Smoking Cessation
Interventions:   Drug: Cost-Free Pharmacotherapy Group;   Other: Prescription Only Group
Sponsors:   Ottawa Heart Institute Research Corporation;   Heart and Stroke Foundation of Ontario
Completed - verified April 2015

Preventing Recurrent Vascular Events in Patients With Stroke or Transient Ischemic Attack

Conditions:   Ischemic Stroke;   Transient Ischemic Attacks
Interventions:   Drug: Antihypertensive agents and lipid lowering therapy;   Other: Usual Care
Sponsors:   University of Alberta;   Heart and Stroke Foundation of Canada;   Alberta Heritage Foundation for Medical Research
Completed - verified April 2015

Montelukast to Treat Bronchiolitis Obliterans

Conditions:   Bronchiolitis Obliterans;   Chronic Graft Versus Host Disease;   Leukotriene;   Montelukast;   Stem Cell Transplant
Intervention:   Drug: Singular (Montelukast Sodium)
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified March 2015

Study to Test the Efficacy and Safety of Drug Eluting vs. Bare-Metal Stents for Saphenous Vein Graft Interventions

Condition:   Coronary Artery Disease
Interventions:   Device: Drug eluting stent;   Device: Bare metal stent
Sponsors:   University Hospital, Basel, Switzerland;   University of Leipzig
Terminated - verified April 2015

Attenuation Corrected Cardiac SPECT Using the GE Hawkeye Camera System

Condition:   Cardiac Disease
Intervention:   Device: GE Attenuation Corrected Hawkeye Camera
Sponsor:   Mayo Clinic
Terminated - verified April 2015

A Trial Using CD133 Enriched Bone Marrow Cells Following Primary Angioplasty for Acute Myocardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Other: CD133+ infusion;   Other: placebo infusion
Sponsors:   Jozef Bartunek;   King's College London
Terminated - verified April 2015

PET and Recovery Following Revascularization (PARR 2)

Conditions:   Coronary Artery Disease;   Ventricular Dysfunction, Left
Interventions:   Procedure: Positron emission tomography: FDG viability imaging;   Other: PET imaging
Sponsors:   Ottawa Heart Institute Research Corporation;   Canadian Institutes of Health Research  (CIHR);   Heart and Stroke Foundation of Ontario
Completed - verified April 2015

Effects Of Atorvastatin On Macrophage Activity And Plaque Inflammation Using Magnetic Resonance Imaging

Conditions:   Atherosclerotic Carotid Disease;   Atheroma;   Atherosclerosis
Intervention:   Drug: atorvastatin
Sponsor:   GlaxoSmithKline
Completed - verified April 2015

Dexamethasone for Cardiac Surgery Trial

Conditions:   Systemic Inflammatory Response Syndrome;   Cardiac Diseases;   Postoperative Complications
Intervention:   Drug: Dexamethasone
Sponsor:   UMC Utrecht
Completed - verified April 2015

Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD

Condition:   Cardiovascular Diseases
Interventions:   Drug: atorvastatin;   Drug: simvastatin
Sponsor:   Pfizer
Completed - verified April 2015

Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke

Condition:   Cardiovascular Disease
Intervention:   Drug: atorvastatin
Sponsor:   Pfizer
Completed - verified April 2015

Scleroderma: Cyclophosphamide or Transplantation (SCOT)

Conditions:   Scleroderma, Systemic;   Sclerosis;   Autoimmune Disease
Interventions:   Procedure: Autologous stem cell transplantation;   Drug: Cyclophosphamide;   Drug: Antithymocyte globulin, equine;   Drug: Methylprednisolone;   Drug: Growth colony stimulating factor (G-CSF);   Radiation: Total body irradiation (TBI)
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting - verified April 2015

Get CardioSmart

You're Invited